Demographic data of study subjects
| Allergic asthma | Healthy | |
|---|---|---|
| N | 14 | 14 |
| Age, mean (range) | 21.5 (19–32) | 21 (19–31) |
| Sex (M/F) | 7/7* | 1/13 |
| FEV1%pred, mean±SD | 105±12 | 110±12 |
| PC20, geometric mean (95% CI) | 2.41 (1.29 to 4.48)*** | >16 |
| PCR-positive for RV16 on day 6, n (%) | 11 (79%) | 9 (64%) |
| RV16 neutralisation on day 42–56, n (%) | 11 (79%) | 9 (64%) |
| Confirmed viral infection†, n (%) | 13 (93%) | 11 (79%) |
| LRTI with RV16, n (% of confirmed) | 10 (77%) | 8 (73%) |
*p<0.05 (χ2 test).
***p<0.001 (Mann–Whitney U test).
†Confirmation by PCR or RV16 neutralisation.
BAL, bronchoalveolar lavage; FEV1%pred, forced expiratory volume in 1 s expressed as percentage of the predicted value; LRTI, lower respiratory tract infection based on positive PCR in bronchial brush, BAL cells or BAL fluid; PC20, provocative methacholine concentration causing a 20% fall in FEV1; RV16, rhinovirus type 16.